Capacity Expansion / Capex
Fredun Pharmaceuticals Expands Manufacturing Capacity with Fifth Facility at Palghar
NSE
NOT LISTED
BSE
539730
Fredun Pharmaceuticals Limited has announced the establishment of a new manufacturing facility in Palghar, Maharashtra, marking its fifth unit. The expansion is aimed at enhancing production capacity, scalability, and supporting growth across key product segments
PRICE-SENSITIVE TRIGGER
Event: Commissioning of New Manufacturing Facility
Type: Capacity Expansion / Capex
Impact: Positive
Immediate Effect: Strengthens manufacturing capabilities and supports future revenue growth through higher production capacity and scalability
Key Metrics:
- New Facility Size: 40,000 sq. ft.
- Planned Expansion: 50,000 sq. ft.
- FY25 Revenue: ₹456 crore
- FY25 EBITDA: ₹55 crore
- FY25 PAT: ₹21 crore
Highlight:
- Expansion aligned with growing demand across pharma and nutraceutical segments
What Happened ?
Fredun Pharmaceuticals Limited announced the addition of a new manufacturing facility in Palghar, Maharashtra.
This marks the company’s fifth manufacturing unit and is part of its broader strategy to strengthen its production footprint and meet increasing demand.
key highlights
Manufacturing Expansion:
- Location: Palghar, Maharashtra
- Facility count: Fifth manufacturing unit
- Initial size: 40,000 sq. ft.
- Additional planned expansion: 50,000 sq. ft.
- Expected operational timeline: By October 2026
- Product coverage:
- Pharmaceutical formulations
- Nutraceuticals
- Veterinary products
- Benefits:
- Improved production scalability
- Enhanced operational efficiency
- Better demand fulfillment (domestic & exports)
- Integration with existing facilities to strengthen network
Note:
Expansion supports export-driven growth, especially in regulated and semi-regulated markets
Risk Analysis
Key Risks
- Delay in commissioning or ramp-up
- Underutilization of new capacity
- Regulatory approvals and compliance
- Demand fluctuations in export markets
- Cost overruns during expansion
Worst Case Scenario
- If demand does not scale as expected, the new facility may operate below optimal utilization, impacting return on investment
Risk Level: Medium
Company Commentary
- Expansion aligns with long-term growth strategy
- Focus on building scalable manufacturing infrastructure
- Commitment to quality, compliance, and innovation
- Aims to strengthen position as a global healthcare manufacturing partner
Official Exchange Filing: Fredun Pharmaceuticals Limited